Scholars Central

Conference abstract

Regulatory transparency: Key aspects throughout access BA/BE report

Authors: Varley Dias Sousa, Damaris Silveira

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Brazil is the 5th biggest pharmaceutical market in the world, and the Brazilian Heath Surveillance Agency (ANVISA) is responsible to evaluate the products quality and safety. Hence, in the field of health regulation, the wide access to data of drugs and related technical documents, especially BA/BE report data, is in expansion at FDA, EMA and ANVISA. A fact to be evaluated is how disclosure policies are built, emphasizing the regulatory impact analysis and detecting the risks and benefits involved. Bioavailability and Bioequivalence Studies (BA/BE) is essentially significant as contain vital information regard drug variability and pharmacokinetic profile over and above is the primary source of information about product efficacy (Generics or multisource products). Discussion: Actually the Brazilian Electronic Database (Sineb) has more than 2000 BA/BE reports of which 30% had negative results, but none of these trials are available for public consultation. Around 300 studies were pilots, performed in order to gain knowledge (Pharmacodynamics/Pharmacokinetic) about the API (Active Product Ingredient). The openness will enable public scrutiny and secondary analysis probably resulting in improvement of the products quality and public health development as well as the social accountability. Over and above the reanalysis will reinforce confidence over Agency´s skills, in the other hand inappropriate reanalysis or methodologically flawed can mislead treatment adherence or public health programs. Conclusion: Responsible public disclosure of BABE reports lead to improve the common knowledge about API characteristics avoiding unnecessary studies as well as protecting voluntaries integrity. However, some boundaries should be respected in order to not frustrate investments on bio-pharmaceutical research and development (R&D) along with not to bias the Agency’s decisionmaking process. After all, decreasing the number of tests imply lowering the registers costs. PDF HTML

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Varley Dias Sousa”
  • BylineArticles whose byline prints “Damaris Silveira”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels